Клиническая, метаболическая и гормональнаяэффективность применения Орлистата у пациентовс метаболическим синдромом
https://doi.org/10.14341/2071-8713-5178
Список литературы
1. Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. РМЖ. 2001; 2(9):56-60.
2. Мкртумян А.М. Ксеникал в комплексной терапии метаболического синдрома. РМЖ. 2001; 2(9):72-73.
3. Cada DJ, Baker DE, Levien T. Orlistat. Hosp Pharm. 1999; 34:1195-213.
4. Colditz GA, Willet WC et al. Weight gain as risk factors for clinical diabetes mellitus in women. Ann Int Med. 1995; 122:481-6.
5. Davison MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduc- tion in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999; 281:235-42.
6. Despres JP, Krauss RM. Obesity and lipoprotein metabolism. In: Bray GA, Bouchard C, James WPT, eds. Handbook of Obesity. New York, NY: Marcel Dekker; 1998; 651-675
7. European Multicentre Orlistat Study Group. Randomised placebo- controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352:167-72.
8. Finer N, James WPT, Kopelman PG et al. One-year treatment of obesity: a random- ized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase ingibitor. Int J Obes. 2000; 24:306-313.
9. Hauptman J, Lucas C, Boldrin MN et al. Orlistat in the long-term treatment of obesi- ty in primary care settings. Arch Fam Med. 2000; 9:160-7.
10. Heymsfield SB, Segal KR, Hauptman J at al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000; 5(8):1321-6.
11. Hill JO, Hauptman J, Anderson JW et al. Orlistat, a lipase inhibitor, for weight main- tenance after conventional dieting: one 1-y study. Am J Clin Nutr. 1999; 69:1108-16.
12. Rossner S, Sjostrom L, Noack R et al. Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity. Obes Res. 2000; 8(1):49-61.
13. Symposium "Orlistat: Ein neuer Ansatz in der Behandlung des adipoesen Typ-2- Diabetikers", im Rahmen der 33.Jahrestagung der Deutschen Diabetes Gesellschaft, May 1998, Leipzig.
14. Targenson JS. XENDOS - a Unique Advantage Abstract Book Satellite Symp, May 2003, Helsinki.
15. Unger RH. Lipotoxic Diseases. Annu Rev Med. 2002; 53:319-36.
Рецензия
Для цитирования:
Ershova E.V., Kolesnikova G.S., Butrova S.A. Клиническая, метаболическая и гормональнаяэффективность применения Орлистата у пациентовс метаболическим синдромом. Ожирение и метаболизм. 2004;1(1):34-37. https://doi.org/10.14341/2071-8713-5178
For citation:
, , Klinicheskaya, metabolicheskaya i gormonal'nayaeffektivnost' primeneniya Orlistata u patsientovs metabolicheskim sindromom. Obesity and metabolism. 2004;1(1):34-37. (In Russ.) https://doi.org/10.14341/2071-8713-5178
Просмотров:
358
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Послать статью по эл. почте 
